NCT06856343招募中不适用
REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- AstraZeneca
- 入组人数
- 126
- 试验地点
- 59
- 主要终点
- Proportion of patients who receive Olaparib for the full treatment duration
研究概览
简要总结
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
详细描述
The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged ≥ 18 years
- •Patient diagnosed with HER2-negative eBC
- •Patient about to be initiated with adjuvant Olaparib at their physician's discretion
- •Patient has been informed and does not object to participation in the study.
排除标准
- •Patient not consenting to participate.
- •Patients included in the Early Access Program
结局指标
主要结局
Proportion of patients who receive Olaparib for the full treatment duration
时间窗: 18 months after inclusion
The primary outcome is the evaluation of the proportion of patients who receive Olaparib for the full treatment duration, described as 12 months of treatment.
次要结局
- BRCA characteristics: Mutation type(18 months after inclusion)
- Type of variants(18 months after inclusion)
- Medical history(18 months after inclusion)
- Time to Olaparib treatment discontinuation(18 months after inclusion)
研究者
研究点 (59)
Loading locations...
相似试验
尚未招募
4 期
Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast CancerBreast Cancer Stage IVNCT06578299Fudan University100
招募中
不适用
FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided TherapyBreast CancerNCT06185569Centre Hospitalier Universitaire de Besancon4,500
Unknown
不适用
H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World StudyAdvanced HR+ HER2 Negative Breast CarcinomaNCT05167643Tianjin Medical University Cancer Institute and Hospital40
终止
1 期
HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025HER2-positive Breast CancerNCT02095210Dorte Nielsen2
进行中（未招募）
不适用
HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)Metastatic CancerNCT04257162SOLTI Breast Cancer Research Group180